Gilead’s $11.9 billion purchase of Kite Pharma in 2017 didn’t follow the ... Late last week, the FDA approved Kite's Tecartus (brexucabtagene autoleucel; formerly KTE-X19) as a treatment ...

Gilead Sciences boasts four approved cancer types between its two CD19 CAR-T products, Yescarta and Tecartus, one being an acute lymphoblastic leukemia indication that Breyanzi doesn’t have.

Story Jan. 10 - Shoreline Biosciences: The cell therapy biotech plans to let go of an undisclosed number of employees tied to a project with Gilead Sciences’ Kite Pharma. Story Jan. 9 - IGM ...

July 10, 2024 — Scientists have discovered a molecular defect that promotes the pathologic immune response in systemic lupus erythematosus (known as lupus) and show that reversing this defect ...

Roche’s Gazyva/Gazyvaro (obinutuzumab) has demonstrated superiority over standard therapy in patients with active lupus nephritis (LN), according to new late-stage data published in the New England ...

Gilead has also been building its oncology pipeline thanks to its acquisition of Kite Pharma which markets cutting-edge CAR-T cancer cell therapies. Immunotherapy is an area where AZ faces tough ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo The U.S. Food and Drug Administration ...

A notable potential in Russia and recovering Africa market further bolster optimism. India's pharma sector has seen remarkable growth in exports, with 99% target already being achieved before FY25, ...

Companies that have grown profits and net profit margins over the past 12 months ...

Natco Pharma Ltd., incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 17,464.11 Crore) operating in Pharmaceuticals sector. Natco Pharma Ltd. key Products/Revenue Segments ...